var title_f28_15_28912="Adult BLS algorithm for healthcare providers";
var content_f28_15_28912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Adult BLS algorithm for healthcare providers: 2010 guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 600px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AED: automated external defibrillator; ALS: advanced life support; BLS: basic life support.",
"     <br>",
"      * The boxes bordered with dashed lines are performed by healthcare providers and not by lay rescuers.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Adult Basic Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28912=[""].join("\n");
var outline_f28_15_28912=null;
var title_f28_15_28913="Vocal fold squamous ca";
var content_f28_15_28913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma right vocal fold",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note exophytic, irregular appearing mass arising from the right anterior true vocal fold.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28913=[""].join("\n");
var outline_f28_15_28913=null;
var title_f28_15_28914="Potassium p-aminobenzoate: Drug information";
var content_f28_15_28914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium p-aminobenzoate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Potaba&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Average dose: 12 g/day in 4-6 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 1 g/10 pounds of weight/day; administer in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Potaba&reg;: 0.5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Potaba&reg;: 0.5 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All forms should be administered after meals or with a snack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: Take with a glass of water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Crush and add to glass of chilled water or juice; stir and drink.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Presently, all indications are classified by the FDA as &ldquo;possibly effective.&rdquo;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of scleroderma, dermatomyositis, morphea, linear scleroderma, pemphigus, Peyronie's disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to potassium p-aminobenzoate or any component of the formulation; concurrent use of sulfonamides",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anorexia: Interrupt therapy if anorexia occurs; may reinstitute once patient improves.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nausea: Interrupt therapy if nausea occurs; may reinstitute once patient improves.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus or a  history of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: Potassium P-Aminobenzoate may diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety for use in pregnancy has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food to avoid stomach upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F211638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (M2 Potassium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $5.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Potaba Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (250): $165.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Potaba Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $67.90",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     P-aminobenzoate is a member of the vitamin B complex family. It may have an antifibrotic effect due to increased oxygen uptake at the tissue level.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10308 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28914=[""].join("\n");
var outline_f28_15_28914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211643\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211653\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211644\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211650\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062205\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211633\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211627\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211635\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211634\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211651\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211637\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211629\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299924\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222474\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211639\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211646\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211640\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211638\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211628\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10308|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_15_28915="APOC countries in Africa";
var content_f28_15_28915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    African Programme for Onchocerciasis Control (APOC) and ex-Onchocerciasis Control Programme (OCP) countries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 640px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     APOC: African Programme for Onchocerciasis Control; OCP: Onchocerciasis Control Programme.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. African Programme for Onchocerciasis Control (APOC). Available at:",
"     <a href=\"file://www.who.int/apoc/countries/en/\" target=\"_blank\">",
"      file://www.who.int/apoc/countries/en/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28915=[""].join("\n");
var outline_f28_15_28915=null;
var title_f28_15_28916="Bexarotene (topical): Drug information";
var content_f28_15_28916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bexarotene (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/0/12293?source=see_link\">",
"    see \"Bexarotene (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7995774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Targretin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9933129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7995512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Cutaneous lesions of T-cell lymphoma:",
"     </b>",
"     Topical: Apply to lesions once every other day for first week, then increase on a weekly basis to once daily, 2 times/day, 3 times/day, and finally 4 times/day, according to tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7995513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7995514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No studies have been conducted; however, renal insufficiency may result in significant protein binding changes and alter pharmacokinetics of bexarotene.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7995515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No studies have been conducted; however, hepatic impairment would be expected to result in decreased clearance of bexarotene due to the extensive hepatic contribution to elimination.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7995572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Targretin&reg;: 1% (60 g) [contains dehydrated ethanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7995450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7995517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Allow gel to dry before covering with clothing. Avoid application to normal skin. Use of occlusive dressings is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7995451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of cutaneous lesions in patients with refractory cutaneous T-cell lymphoma (stage 1A and 1B) or who have not tolerated other therapies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7995449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7995490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (14%), weakness (6%), pain (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (14% to 72%), pruritus (6% to 40%), contact dermatitis (14%), exfoliative dermatitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperlipidemia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia (6%), lymphadenopathy (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough (6%), pharyngitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (6%), infection (18%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7995486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bexarotene or any component of the formulation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7995487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukopenia: Leukopenia and neutropenia may occur (may be delayed); monitor for signs and symptoms of infection about 4-8 weeks after initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Induces significant lipid abnormalities in a majority of patients (triglyceride, total cholesterol, and HDL); reversible on discontinuation. Use extreme caution in patients with underlying hypertriglyceridemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use only with extreme caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin A: Limit additional vitamin A intake to &lt;15,000 units/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      Bexarotene is a retinoid, a drug class associated with birth defects in humans; do not administer during pregnancy.",
"     </b>",
"     Pregnancy test needed 1 week before initiation and every month thereafter. Effective contraception must be in place 1 month before initiation, during therapy, and for at least 1 month after discontinuation. Male patients with sexual partners who are pregnant, possibly pregnant, or who could become pregnant, must use condoms during sexual intercourse during treatment and for 1 month after last dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7995493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7995494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8043195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7998914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bexarotene is a retinoid, a drug class associated with birth defects in humans; do not administer during pregnancy.",
"     </b>",
"     Bexarotene caused birth defects when administered orally to pregnant rats. It must not be given to a pregnant woman or a woman who intends to become pregnant. If a woman becomes pregnant while using the gel, it must be stopped immediately and appropriate counseling be given. In women of childbearing potential, therapy should be started on the second or third day of a normal menstrual period. Either abstinence or two forms of reliable contraception (one should be nonhormonal) must be used for at least 1 month before initiating therapy, during therapy, and for 1 month following discontinuation of bexarotene. A negative pregnancy test (sensitivity of at least 50 mIU/mL) within 1 week prior to beginning therapy, and monthly thereafter is required for women of childbearing potential. Males patients must use a condom during any sexual contact with women of childbearing age during therapy, and for 1 month following discontinuation of bexarotene",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8043196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9770109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bexarotene is excreted into breast milk. Due to the potential for serious adverse reactions in a nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Targretin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 g): $4149.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9773407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If female, pregnancy test 1 week before initiation then monthly while on bexarotene; lipid panel before initiation, then weekly until lipid response established and then at 8-week intervals thereafter; baseline LFTs, repeat at 1, 2, and 4 weeks after initiation then at 8-week intervals thereafter if stable; baseline and periodic thyroid function tests; baseline CBC with periodic monitoring",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7995501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism is unknown. Binds and activates retinoid X receptor subtypes. Once activated, these receptors function as transcription factors that regulate the expression of genes which control cellular differentiation and proliferation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9770110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Systemically absorbed following topical application (1% gel: &lt;55 ng/mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lowe MN and Plosker GL, \"Bexarotene,\"",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2000, 1(4):245-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin AG, \"Bexarotene Gel: A New Skin-Directed Treatment Option for Cutaneous T-Cell Lymphomas,\"",
"      <i>",
"       J Drugs Dermatol",
"      </i>",
"      , 2003, 2(2):155-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28916/abstract-text/12852367/pubmed\" id=\"12852367\" target=\"_blank\">",
"        12852367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9011 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28916=[""].join("\n");
var outline_f28_15_28916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995774\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9933129\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995512\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995513\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995514\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995515\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995572\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995450\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995517\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995451\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995449\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995490\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995487\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995493\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995494\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043195\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998914\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043196\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770109\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322021\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773407\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995501\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770110\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9011\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9011|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/11/28854?source=related_link\">",
"      Bexarotene (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/14/36069?source=related_link\">",
"      Bexarotene (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/0/12293?source=related_link\">",
"      Bexarotene (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_15_28917="Dextroamphetamine: Patient drug information";
var content_f28_15_28917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dextroamphetamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     see \"Dextroamphetamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     see \"Dextroamphetamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexedrine&reg; Spansule&reg;;",
"     </li>",
"     <li>",
"      ProCentra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexedrine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat narcolepsy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701921",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dextroamphetamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Both attention deficit/hyperactivity problems and Tourette's syndrome or tics, drug abuse, glaucoma, heart disease, high blood pressure, nervous state, overactive thyroid disease, or structure problems of the heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12368 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28917=[""].join("\n");
var outline_f28_15_28917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158794\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158795\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029484\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029486\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029485\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029490\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029491\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029493\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029488\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029489\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029494\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029495\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=related_link\">",
"      Dextroamphetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=related_link\">",
"      Dextroamphetamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_15_28918="Methyldopa: Drug information";
var content_f28_15_28918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyldopa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/6/29797?source=see_link\">",
"    see \"Methyldopa: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/10/20645?source=see_link\">",
"    see \"Methyldopa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methyldopa&reg;;",
"     </li>",
"     <li>",
"      Nu-Medopa",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 250 mg 2-3 times/day; increase every 2 days as needed (maximum dose: 3 g/day); usual dose range (JNC 7): 250-1000 mg/day in 2 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     When administered with other antihypertensives other than thiazide diuretics, limit initial daily dose of methyldopa to 500 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     250-1000 mg every 6-8 hours; maximum: 1 g every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F195059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/10/20645?source=see_link\">",
"      see \"Methyldopa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 10 mg/kg/day in 2-4 divided doses; increase every 2 days as needed to maximum dose of 65 mg/kg/day. Do not exceed 3 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     5-10 mg/kg/dose every 6-8 hours up to a total  maximum daily dose of 65 mg/kg/day or 3 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Initiate at the lower end of the dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F195039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 8-12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 12-24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (administer after hemodialysis on dialysis days): Moderately dialyzable (up to 60% with a 6-hour session) (Yeh, 1970).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administer every 12-24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer every 8-12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Use of antihypertensives in patients requiring CRRT is generally not recommended since CRRT is typically employed when patient cannot tolerate intermittent hemodialysis due to hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14477031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, use is contraindicated in patients with active hepatic disease (eg, acute hepatitis and cirrhosis).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse over 30-60 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer new dosage increases in the evening to minimize sedation.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, sodium bicarbonate 5%, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol, heparin, meperidine, morphine, theophylline.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     TPN.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methyldopa may be confused with L-dopa, levodopa",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris aggravation, bradycardia, carotid sinus hypersensitivity prolonged, heart failure, myocarditis, orthostatic hypotension, paradoxical pressor response (I.V. use), pericarditis, peripheral edema, symptoms of cerebrovascular insufficiency, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bell&rsquo;s palsy, dizziness, drug fever, headache, lightheadedness, mental acuity decreased, mental depression, nightmares, parkinsonism, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast enlargement, gynecomastia, hyperprolactinemia, lactation, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, colitis, constipation, diarrhea, flatulence, nausea, pancreatitis, sialadenitis, sore or &ldquo;black&rdquo; tongue, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bone marrow suppression, eosinophilia, granulocytopenia, hemolytic anemia; positive tests for ANA, LE cells, rheumatoid factor, Coombs test (positive); leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal LFTs, liver disorders (hepatitis), jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, choreoathetosis, myalgia, paresthesias, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: SLE-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methyldopa or any component of the formulation; active hepatic disease; liver disorders previously associated with use of methyldopa; concurrent use of  MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: May produce clinical edema; discontinue if edema worsens or signs of heart failure arise. Mild edema may be controlled with the concomitant use of diuretic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Rare cases of reversible granulocytopenia and thrombocytopenia have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     May rarely produce hemolytic anemia; positive Coombs' test occurs in 10% to 20% of patients usually occurring between 6 and 12 months of therapy; perform CBC periodically. If Coombs'-positive hemolytic anemia occurs during therapy, discontinue use and do not reinitiate; Coombs&rsquo; test may not revert back to normal for weeks to months following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May rarely produce liver disorders including fatal hepatic necrosis; use with caution in patients with previous liver disease or dysfunction. Periodically monitor liver function during the first 6-12 weeks of therapy or when unexplained fever occurs; discontinue use if fever, abnormal liver function tests, or jaundice is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular effects: Patients with severe bilateral cerebrovascular disease have exhibited involuntary choreoathetotic movements (rare); discontinue use if these symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Usually transient, sedation may occur with initiation or whenever the dose is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may respond to smaller doses. The active metabolites of methyldopa accumulate in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use due to high risk of CNS adverse effects; may also cause orthostatic hypotension and bradycardia; not recommended for routine use as an antihypertensive (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Do not use injectable if bisulfite allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: May occur usually between the second and third month of therapy; adding a diuretic or increasing the dosage of methyldopa frequently restores blood pressure control.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Methyldopa may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Methyldopa.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Methyldopa. Management: Consider separating doses of these products by 2 or more hours to minimize this interaction; however, the success of this action appears limited.  Monitor for decreased therapeutic effects of methyldopa with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F195028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression). Avoid natural licorice (causes sodium and water retention and increases potassium loss). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (injectable) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Methyldopa crosses the placenta and appears in cord blood. Methyldopa is considered an appropriate agent for the treatment of hypertension in pregnancy (ACOG, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F195018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary requirements for vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folate may be increased with high doses of methyldopa.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methyldopate HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (5 mL): $48.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methyldopa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $38.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $68.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (standing and sitting/lying down), CBC, liver enzymes (periodically during the first 6-12 weeks or when unexplained fever occurs), Coombs' test (direct) (may obtain prior to initiation and at 6 and 12 months); blood pressure monitor required during I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adopal (FI);",
"     </li>",
"     <li>",
"      Aldin (TW);",
"     </li>",
"     <li>",
"      Aldomet (AE, AR, AU, BE, BF, BH, BJ, BR, CH, CI, CR, CY, DK, EG, ES, ET, FR, GB, GH, GM, GN, GR, GT, HN, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, SV, SY, TN, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Aldomet-Forte (HK);",
"     </li>",
"     <li>",
"      Aldometil (AT);",
"     </li>",
"     <li>",
"      Alfamet (TR);",
"     </li>",
"     <li>",
"      Alphadopa (IN);",
"     </li>",
"     <li>",
"      Bekanta (JP);",
"     </li>",
"     <li>",
"      Domecin (JP);",
"     </li>",
"     <li>",
"      Dopagyt (IN);",
"     </li>",
"     <li>",
"      Dopamet (HK, ID, NO, PH);",
"     </li>",
"     <li>",
"      Doparine (PH);",
"     </li>",
"     <li>",
"      Dopegyt (AE, BB, BG, BH, BM, BS, BZ, CY, CZ, EG, GY, HU, IL, IQ, IR, JM, JO, KW, LB, LY, MY, OM, PL, PR, QA, RU, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Emdopa (IN);",
"     </li>",
"     <li>",
"      Hy-po-tone (ZA);",
"     </li>",
"     <li>",
"      Hydopa (AU);",
"     </li>",
"     <li>",
"      Hypolag (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Medopa (JP, TH);",
"     </li>",
"     <li>",
"      Mefpa (TH);",
"     </li>",
"     <li>",
"      Methoplain (JP);",
"     </li>",
"     <li>",
"      Metildopa (CN, HR);",
"     </li>",
"     <li>",
"      Metpata (TH);",
"     </li>",
"     <li>",
"      Normopress (ZA);",
"     </li>",
"     <li>",
"      Pharmet (ZA);",
"     </li>",
"     <li>",
"      Presinol (AT, DE);",
"     </li>",
"     <li>",
"      Presinol 500 (DE);",
"     </li>",
"     <li>",
"      Prodopa (NZ);",
"     </li>",
"     <li>",
"      Rivapress (TW);",
"     </li>",
"     <li>",
"      Sembrina (BF, BJ, CI, ET, FI, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Siamdopa (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulation of central alpha-adrenergic receptors by a false neurotransmitter (alpha-methylnorepinephrine) that results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Hypotensive: Oral, I.V.: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: Single-dose: 12-24, Multiple-dose: 24-48 hours; I.V.: 10-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Incomplete due to presystemic gut metabolism (Skerjanec, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.23 L/kg (Myhre, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 15% (Myhre, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Intestinal and hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~42% (Skerjanec, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.5-2 hours; End-stage renal disease: Prolonged (Myhre, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 2-4 hours (Myhre, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70% as parent drug and metabolites); excretion complete within 36 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, \"ACOG Practice Bulletin No. 125: Chronic Hypertension in Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      ,  2012, 119(2 Pt 1):396-407.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/22270315/pubmed\" id=\"22270315\" target=\"_blank\">",
"        22270315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD,",
"      <i>",
"       Miller&rsquo;s Anesthesia",
"      </i>",
"      ,  7th ed, Philadelphia PA: Churchill Livingstone, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD, Way WL, and Eger EI, &ldquo;The Effects of Alpha-Methyldopa, Reserpine, Guanethidine, and Iproniazid on Minimum Alveolar Anesthetic Requirement (MAC),&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1968, 29(6):1153-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/5726752/pubmed\" id=\"5726752\" target=\"_blank\">",
"        5726752",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myhre E, Rugstad HE, and Hansen T, &ldquo;Clinical Pharmacokinetics of Methyldopa,&rdquo;",
"      <i>",
"       ClinPharmacokinet",
"      </i>",
"      , 1982, 7(3):221-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/7047042 /pubmed\" id=\"7047042 \" target=\"_blank\">",
"        7047042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newton DW, Fung EY, and Williams DA, &ldquo;Stability of Five Catecholamines and Terbutaline Sulfate in 5% Dextrose Injection in the Absence and Presence of Aminophylline,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1981, 38(9):1314-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/7282714/pubmed\" id=\"7282714\" target=\"_blank\">",
"        7282714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skerjanec A, Campbell NR, Robertson S, et al, &ldquo;Pharmacokinetics and Presystemic Gut Metabolism of Methyldopa in Healthy Human Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1995, 35(3):275-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/7608316/pubmed\" id=\"7608316\" target=\"_blank\">",
"        7608316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeh BK, Dayton PG, and Waters WC 3rd, &ldquo;Removal of Alpha-Methyldopa (Aldomet) in Man by Dialysis,&rdquo;",
"      <i>",
"       Proc Soc Exp Biol Med",
"      </i>",
"      , 1970, 135(3):840-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28918/abstract-text/5486722/pubmed\" id=\"5486722\" target=\"_blank\">",
"        5486722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9635 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-217.117.136.88-59DAAF2E3B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28918=[""].join("\n");
var outline_f28_15_28918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195081\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195037\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195059\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195038\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195039\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14477031\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194989\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195010\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195088\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195009\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195090\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195079\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195013\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194993\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299698\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194998\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195028\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195001\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195016\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195043\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195018\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195015\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195004\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195019\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194992\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195012\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/6/29797?source=related_link\">",
"      Methyldopa: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/10/20645?source=related_link\">",
"      Methyldopa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_15_28919="Fosinopril and hydrochlorothiazide: Drug information";
var content_f28_15_28919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosinopril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/48/29445?source=see_link\">",
"    see \"Fosinopril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Monopril-HCT&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Monopril-HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: Fosinopril 10-80 mg per day, hydrochlorothiazide 12.5-50 mg per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A patient whose blood pressure is not adequately controlled with fosinopril or hydrochlorothiazide monotherapy may be switched to combination therapy.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or serum creatinine &ge;3 mg/dL: Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with impaired hepatic function from progressive liver disease. Metabolism of fosinopril to its active metabolite, fosinoprilat, will be reduced as will clearance of fosinoprilat.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 10/12.5: Fosinopril sodium 10 mg and hydrochlorothiazide 12.5 mg; 20/12.5: Fosinopril sodium 20 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monopril-HCT&reg; 10/12.5: Fosinopril sodium 10 mg and hydrochlorothiazide 12.5 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monopril-HCT&reg; 20/12.5: Fosinopril sodium 20 mg and hydrochlorothiazide 12.5 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; not indicated for first-line treatment",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Monopril&reg; may be confused with Accupril&reg;, minoxidil, moexipril, Monoket&reg;, Monurol&reg;, ramipril",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Reactions reported with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7%, less than placebo), fatigue (4%), dizziness (3%), orthostatic hypotension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (6%), upper respiratory infection (2%, less than placebo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Angioedema, breast mass, chest pain, depression, diarrhea, dysuria, edema, eosinophilia, esophagitis, gastritis, gout, hepatic necrosis, leukopenia, libido change, liver function test elevations (transaminases, LDH, alkaline phosphatase, serum bilirubin), neutropenia, numbness, paresthesia, rhythm disturbances, sexual dysfunction, syncope, tinnitus, urinary tract infection, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to fosinopril, any other ACE inhibitor, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use enalapril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use fosinopril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use ACE inhibitors with caution in pre-existing renal insufficiency; not recommended for use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or serum creatinine &ge;3 mg/dL. Avoid rapid dosage escalation which may lead to further renal impairment. Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Thiazide diuretics can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Based on human data, ACEIs can cause injury and death to the developing fetus when used in the second and third trimesters. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F174485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Hydrochlorothiazide peak serum levels may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai (has estrogenic activity, may also cause photosensitization). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (1st trimester); D (2nd and 3rd trimester) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Based on human data, ACEIs can cause injury and death to the developing fetus when used in the second and third trimesters. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13857793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fosinopril Sodium-HCTZ Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (100): $154.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (100): $154.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F174482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dynacil (DE);",
"     </li>",
"     <li>",
"      Elidiur (IT);",
"     </li>",
"     <li>",
"      Fosicomp (CH);",
"     </li>",
"     <li>",
"      Fosinorm (DE);",
"     </li>",
"     <li>",
"      Fositen Plus (PT);",
"     </li>",
"     <li>",
"      Foziretic (FR);",
"     </li>",
"     <li>",
"      Monoplus (AU, BR);",
"     </li>",
"     <li>",
"      Monopril Plus (CO);",
"     </li>",
"     <li>",
"      Monozide (BG, EE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosinopril is a competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure. Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28919/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28919/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/15/28919/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8952 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28919=[""].join("\n");
var outline_f28_15_28919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708813\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174489\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174490\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174507\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174493\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174494\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174495\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174496\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174475\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174459\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174476\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174513\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174505\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174479\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174463\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299367\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174467\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174485\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174470\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174481\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174497\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13857793\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524621\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174473\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174482\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174462\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174478\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/48/29445?source=related_link\">",
"      Fosinopril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_15_28920="Erythema marginatum on trunk";
var content_f28_15_28920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50841%7ERHEUM%2F71804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50841%7ERHEUM%2F71804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema marginatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image of the back of a patient with acute rheumatic fever shows the characteristic rash, erythema marginatum. Note the erythematous lesions with pale centers and rounded or serpiginous margins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Binotto, MA, Guilherme, L, Tanaka, AC. Rheumatic fever. Images Paediatr Cardiol 2002; 11:12. Copyright &copy; 2002 Images in Paediatric Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema marginatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A closer view of erythema marginatum in a patient with acute rheumatic fever.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Binotto, MA, Guilherme, L, Tanaka, AC. Rheumatic fever. Images Paediatr Cardiol 2002; 11:12. Copyright &copy; 2002 Images in Paediatric Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28920=[""].join("\n");
var outline_f28_15_28920=null;
var title_f28_15_28921="Preeclampsia electron micrograph";
var content_f28_15_28921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preeclampsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in preeclampsia showing narrowing of the capillary lumen due to expansion of the mesangium, swelling of the endothelial (Endo) cell cytoplasm (arrow), and subendothelial deposition of hyaline (Hy) material which represents large macromolecules such as IgM. The damaged endothelial cell has become partially separated (*) from the glomerular basement membrane (GBM).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28921=[""].join("\n");
var outline_f28_15_28921=null;
var title_f28_15_28922="Treatment of idiopathic nephrotic syndrome in children";
var content_f28_15_28922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of idiopathic nephrotic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/15/28922/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/15/28922/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/15/28922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/15/28922/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/15/28922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/15/28922/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/15/28922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome (NS) is caused by renal diseases that increase the permeability of the glomerular filtration barrier. It is classically characterized by four clinical features, but the first two are generally used for a clinical diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrotic range proteinuria &ndash; Urine protein excretion &gt;50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or a spot urine sample with a ratio",
"      <span class=\"nowrap\">",
"       (U",
"       <sub>",
"        P",
"       </sub>",
"       /U",
"       <sub>",
"        Cr",
"       </sub>",
"       )",
"      </span>",
"      greater than 3 mg of protein per mg creatinine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H13#H13\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Urine protein excretion'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypoalbuminemia &ndash; Serum albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Idiopathic NS is the most common form of NS in children. It is characterized by diffuse foot process effacement on electron microscopy and a variety of findings on light microscopy that include minimal changes, focal segmental glomerulosclerosis (FSGS), or mesangial proliferation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Idiopathic nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the treatment of idiopathic NS in children is presented here. The etiology, clinical manifestations, and diagnosis of NS in children are discussed separately. In addition, specific diseases that cause idiopathic NS are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=see_link\">",
"     \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic nephrotic syndrome (NS) is characterized by diffuse foot process effacement on electron microscopy and a variety of findings on light microscopy that include minimal changes, focal segmental glomerulosclerosis (FSGS), or mesangial proliferation. In children, the most common histologic form of idiopathic NS is with minimal changes, referred to as minimal change disease (MCD), occurring in about 75 percent of pediatrics cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/1\">",
"     1",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Prior to 1940, the mortality rate in children with NS was 40 percent, primarily due to infection, but has been significantly reduced with the introduction of steroid treatment and antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with MCD are generally responsive to steroid therapy. Because clinical findings are highly predictable in differentiating MCD from other forms of NS, steroid therapy can be initiated in patients who are likely to have MCD based upon clinical criteria without histological confirmation by renal biopsy. Up to one third of patients with FSGS will also initially respond to steroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Idiopathic nephrotic syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H20#H20\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Initial therapy versus renal biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical experience has demonstrated that the response to steroid therapy rather than the histologic features seen on renal biopsy is better at predicting long-term prognosis. Patients who respond to steroids have an excellent prognosis and rarely develop end stage renal failure. As a result, patients with NS can be defined by their response to steroid therapy as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroid-sensitive NS &ndash; More than 90 percent of patients who respond to steroid therapy have MCD, and FSGS is primarily seen in the remaining patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"       2",
"      </a>",
"      ]. Almost all patients with steroid-sensitive NS have an excellent outcome with few patients developing end stage renal disease or chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Steroid-sensitive nephrotic syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Steroid-resistant NS &ndash; One-fourth of patients who fail to respond to steroids will have MCD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients who fail an initial course of steroid therapy should undergo renal biopsy to determine the underlying diagnosis to guide further therapeutic choices. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=see_link\">",
"       \"Steroid-resistant idiopathic nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25158738\">",
"    <span class=\"h1\">",
"     SOCIETAL GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several societies have established guidelines to manage pediatric nephrotic syndrome that all initiate therapy with corticosteroid therapy (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    ). The following discussion is consistent with the Children&rsquo;s Nephrotic Syndrome Consensus and the Kidney Disease: Improving Global Outcomes (KDIGO) practice guidelines to treat pediatric nephrotic syndrome, which are presented below. Symptomatic support and treatment of complications of nephrotic syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link\">",
"     \"Complications of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=see_link\">",
"     \"Symptomatic management of nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Children's Nephrotic Syndrome Consensus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, the Children's Nephrotic Syndrome Consensus Conference, which included pediatric nephrologists from the southeast and midwest sections of the United States, developed the following guidelines for the treatment of children with nephrotic syndrome (NS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial therapy &ndash; Initial",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for six weeks, followed by alternate-day prednisone of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for an additional six weeks.",
"     </li>",
"     <li>",
"      First",
"      <span class=\"nowrap\">",
"       relapse/Infrequent",
"      </span>",
"      relapse &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      therapy of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for four weeks.",
"     </li>",
"     <li>",
"      Frequent relapses &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      therapy of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for four weeks, which is then tapered over two months by 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day. In this guideline, steroid-sparing agents, such as oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil may be used to sustain remission and thereby reduce cumulative steroid doses and toxicity. However, in our experience, these patients usually do not require steroid sparing agents because low dose alternate-day prednisone is effective in preventing frequent relapses and is well tolerated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Frequent relapsing/steroid dependent NS'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Steroid-dependent disease &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      remains the preferred therapy in the absence of significant steroid toxicity. Steroid-sparing agents, such as levamisole,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and calcineurin inhibitors (ie,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ), may be helpful in reducing steroid dosing. However, there are no data based upon controlled trials in helping to chose among these agents, and drug selection is based upon the",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratio of each agent as determined by the clinician. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Nonsteroidal therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Steroid-resistant disease &ndash; Therapy is based upon the histologic findings found on renal biopsy. Additional treatment includes angiotensin antagonism and supportive care focused on managing the complications of nephrotic syndrome (eg, edema, hypertension, infection, dyslipidemia, and thromboembolism). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=see_link\">",
"       \"Steroid-resistant idiopathic nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25158857\">",
"    <span class=\"h2\">",
"     KDIGO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney Disease: Improving Global Outcomes (KDIGO) was established in 2003 and is an international organization focused on improving the outcome of patients with kidney disease globally. In 2012, a working committee developed the following guidelines to manage children with steroid-sensitive nephrotic syndrome as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial therapy &ndash; Initial",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy of 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for four to six weeks (maximum dose of 60",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      followed by alternate-day prednisone of 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose of 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and continued for two to five months with tapering of the dose.",
"     </li>",
"     <li>",
"      Infrequent relapses &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      therapy of 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose of 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone of 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose of 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for at least four weeks. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial or infrequent relapse'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Frequent relapses or steroid-dependent disease &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      therapy of 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose of 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone for at least three months. The dose of alternate-day prednisone should be the lowest dose needed to maintain remission without adverse side effects. In patients in whom alternate-day therapy is not effective in maintaining remission, the lowest possible dose of daily prednisone is given to maintain remission to minimize adverse side effects. Daily prednisone should be given to patients during episodes of upper respiratory tract infection and other infections that are associated with relapse. (See",
"      <a class=\"local\" href=\"#H81224475\">",
"       'Infections as relapse triggers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Corticosteroid-sparing agents should be given to children with frequently relapsing or steroid-dependent disease who develop steroid-related adverse effects. Data are insufficient to choose among the following agents. Drug selection is based on the reported efficacy, adverse effects, local availability, and cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alkylating agents include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 8 to 12 weeks [maximum cumulative dose of 168",
"      <span class=\"nowrap\">",
"       mg/kg])",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"       chlorambucil",
"      </a>",
"      (dose of 0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 8 weeks [maximum cumulative dose 11.2",
"      <span class=\"nowrap\">",
"       mg/kg]).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H81224860\">",
"       'Alkylating agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Levamisole (dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on alternate days for at least 12 months). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Levamisole'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Calcineurin inhibitors include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (initial dose of 4 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day given in two divided doses)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (initial dose of 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day given in two divided doses). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil (initial dose of 1200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day given in two divided doses for at least 12 months). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mycophenolate'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       Rituximab",
"      </a>",
"      (an anti-CD20 monoclonal) should be considered only in children who have failed combination therapy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      and other corticosteroid-sparing agents and have serious adverse effects of therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Rituximab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Both mizoribine and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      are",
"      <strong>",
"       NOT",
"      </strong>",
"      recommended in the management of children with NS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the most common cause of pediatric idiopathic nephrotic syndrome (NS) is minimal change disease (MCD), which is generally responsive to steroid therapy. As a result, empirical steroid therapy is given to patients with a high probability of having MCD without confirmation of the diagnosis by renal biopsy. MCD can be clinically differentiated from other causes of NS in children. Thus, therapy can be started in patients who fulfill",
"    <strong>",
"     all",
"    </strong>",
"    of the following clinical criteria for MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H20#H20\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Initial therapy versus renal biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age older than 1 year and younger than 10 years of age",
"     </li>",
"     <li>",
"      None of the following findings: hypertension, gross hematuria, and a marked elevation in serum creatinine",
"     </li>",
"     <li>",
"      Normal complement levels",
"     </li>",
"     <li>",
"      No extra-renal symptoms such as malar rash or purpura",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although steroid therapy is often started immediately following the diagnosis of NS, it should be stressed that spontaneous remission occurs in 5 percent of cases within one or two weeks. Therefore, the initiation of steroid therapy may be delayed for a few days or a week [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older children, a renal biopsy is recommended because of the increase in prevalence of diagnoses other than MCD in this age group. In these patients, therapeutic decisions are based on the histologic diagnosis, which are discussed separately for each specific disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=see_link\">",
"     \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=see_link\">",
"     \"Evaluation and treatment of membranoproliferative glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Steroid response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with idiopathic NS will respond to steroid therapy with complete resolution of proteinuria (ie, urinary protein excretion &lt; 4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per hour or 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter study from the International Society of Kidney Disease in Children (ISKDC) of 334 children with MCD, ninety-two percent of patients responded to steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/5\">",
"     5",
"    </a>",
"    ]. Six months after steroid therapy, the following outcomes were noted in the steroid-responsive patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 40 percent of patients did not relapse within six months after the initial course of steroid therapy. In this group of patients, long-term follow-up demonstrated 16 percent had no further relapse, and 60 percent only had rare relapses (defined as no two-year consecutive periods with one or more relapses per year).",
"     </li>",
"     <li>",
"      About 30 percent relapsed frequently (defined as two or more relapses within six months after initial steroid therapy).",
"     </li>",
"     <li>",
"      20 percent had a single relapse within the six month time period.",
"     </li>",
"     <li>",
"      Three percent of patients who initially responded to steroid therapy failed to respond to subsequent courses of steroid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168505\">",
"    <span class=\"h3\">",
"     Time to response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who respond to steroid therapy will do so within the first four weeks of therapy. This was illustrated in another report from the ISKDC that demonstrated 90 percent of responding patients had attained complete remission within four weeks after beginning therapy, and the remaining 10 percent responded after an additional two to four more weeks of daily steroid therapy (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"UTD.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"     2",
"    </a>",
"    ]. A short response time of less than seven days is associated with a better prognosis including less likelihood of relapsing within three months, frequent relapses, and steroid dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168465\">",
"    <span class=\"h3\">",
"     Length of therapy and risk of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;A longer duration of the initial course of steroids appears to reduce the risk of relapse and decreases the cumulative dose of steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The beneficial prolonged course includes periods of daily and alternate-day steroids.",
"   </p>",
"   <p>",
"    This was illustrated by a meta-analysis that concluded initial steroid therapy should be at least three months duration in children with idiopathic nephrotic syndrome to reduce the risk of subsequent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/12\">",
"     12",
"    </a>",
"    ]. This conclusion was based on the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pooled analysis from six trials, treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      for three to seven months versus a two month regimen reduced the risk of relapse at 12 to 24 months post-therapy (RR 0.70, 95% CI 0.58-0.84). There was no difference in cumulative steroid dose.",
"     </li>",
"     <li>",
"      In a pooled analysis of four trials of 382 children, the risk of relapse was lower with six versus three months of therapy (RR 0.57, 95% CI 0.45-0.71). There was no difference in cumulative steroid dose.",
"     </li>",
"     <li>",
"      There was an inverse linear relationship between treatment duration and the risk of relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were seen in a randomized controlled trial from the Arbeitsgemeinshaft f&uuml;r P&auml;diatrische Nephrologie (APN) that reported a lower relapse rate 12 months after discontinuation of therapy with a 12-week versus an 8-week course of steroid therapy (36 versus 61 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Slow tapering to avoid adrenal suppression may be important to maintain long-term remission as demonstrated in a small study that reported moderate to severe post-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    adrenal suppression was associated with an increased risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing initial immunosuppression by adding",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to steroid therapy had been proposed as a way to reduce the relapse rate. However, the addition of cyclosporine does not alter the two-year relapse rate and the combination of cyclosporine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    compared with prednisone alone results in a greater number of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As a result, steroids alone are used as the initial therapy for childhood NS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167764\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is variation in the dosing and duration of therapy, almost all pediatric nephrologists empirically treat children with idiopathic NS with a prolonged course of steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/16\">",
"     16",
"    </a>",
"    ]. Based upon the currently available data, we initially treat children with idiopathic NS who are likely to have minimal change disease with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day (maximum of 60",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    With the initiation of steroid therapy, patients and their parents are taught to monitor urine protein levels by urine dipstick [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/17\">",
"     17",
"    </a>",
"    ]. When proteinuria disappears,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    is continued at the same dose for 30 days, and the patient is then switched to alternate-day therapy (at the same daily dose) for two months. Thereafter, the alternate-day dose is decreased every two weeks by 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    The net effect is that the total duration of initial therapy typically is 4.5 months.",
"   </p>",
"   <p>",
"    In our practice, among patients who are not in remission after four weeks of daily steroid therapy, we administer three pulses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ) every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/18\">",
"     18",
"    </a>",
"    ]. This regimen is associated with fewer side effects than prolongation of daily high-dose steroids (advocated by others in the field as discussed below), and may produce remission more quickly in the few patients who would have entered the second month of daily glucocorticoid therapy. Patients who have persistence of proteinuria one week after this treatment are considered steroid-resistant. A renal biopsy is performed in these patients with steroid-resistant NS, as there is increased likelihood that they have another glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"     2",
"    </a>",
"    ]. No additional steroid therapy is administered until a histologic diagnosis is made, which aids in making therapeutic choices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=see_link\">",
"     \"Steroid-resistant idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, other centers do not administer intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    as standard practice in refractory patients, and may use one of the following alternate approaches in patients who are not in remission after an initial four-week course of daily steroid therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsy patients without administering the three pulses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , as there is an increased likelihood that they have another glomerular disease that may not be responsive to additional steroid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=see_link\">",
"       \"Steroid-resistant idiopathic nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continue daily steroid therapy for another four weeks because an additional 10 percent of steroid responsive patients will respond after four weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients who fail to respond to a maximum eight weeks of daily steroid therapy are considered steroid-resistant and require a renal biopsy to determine the underlying glomerular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Steroid-resistant nephrotic syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The approach outlined by the Children&rsquo;s Nephrotic Syndrome Consensus conference uses a daily dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (maximum 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for six weeks followed by alternate-day steroids of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for an additional six weeks. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Children's Nephrotic Syndrome Consensus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174702423\">",
"    <span class=\"h2\">",
"     Outcome based upon response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the previously mentioned report from the ISKDC, the long-term outcome of 389 children with minimal change disease (mean follow-up of 9.4 years) were reported based on their initial response to steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/5\">",
"     5",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, 95 percent of children did well. Only 4 to 5 percent died from complications (eg, peritonitis) or progressed to end-stage renal disease (ESRD).",
"     </li>",
"     <li>",
"      Prognosis was best in the steroid-responsive patients who did not relapse in the first six months. Approximately 75 percent either continued in remission during follow-up or relapsed rarely. Only 4 percent became frequent relapsers.",
"     </li>",
"     <li>",
"      Patients with persistent proteinuria after eight weeks of steroid therapy (steroid-resistant) had a 21 percent risk of progression to ESRD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STEROID-SENSITIVE NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the majority of children with idiopathic nephrotic syndrome (NS) has minimal change disease (MCD) and will attain complete remission with an initial course of steroid therapy. However, 80 to 90 percent of steroid-responsive patients will experience one or more subsequent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/5,12,19\">",
"     5,12,19",
"    </a>",
"    ]. As a result, management for patients with steroid-sensitive NS (SSNS) is focused on early detection and treatment of any relapse to reduce the risk of complications associated with NS. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Frequent relapsing/steroid dependent NS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient responds to steroid therapy, ongoing monitoring for proteinuria is required to detect relapses early and initiate therapy to prevent significant fluid accumulation (edema) and minimize the complications associated with childhood idiopathic NS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link\">",
"     \"Complications of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients and their parents are taught to routinely measure body weight as well as continuing to monitor urine protein levels by urine dipstick [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/17\">",
"     17",
"    </a>",
"    ]. Increased urinary protein concentration typically provides the first indication of a relapse. When this occurs, the family should call their health care provider for instructions regarding management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81224482\">",
"    <span class=\"h2\">",
"     Steroid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     Prednisone",
"    </a>",
"    remains the preferred therapy in the children with SSNS as long as there is no significant steroid toxicity. The regimen of steroid therapy is dependent on the course of the disease (eg, frequency of relapses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Initial or infrequent relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the first initial relapses or for infrequent relapses, steroid therapy is typically administered at a dose of 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day (maximum dose of 60",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    The length of steroid therapy varies among pediatric nephrologists. In our practice, daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    is given until proteinuria has disappeared for four to five days. Alternate-day therapy is then begun and the dose tapered to 15 to 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every other day for another four weeks.",
"   </p>",
"   <p>",
"    This is similar to the approach by the Children&rsquo;s Nephrotic Syndrome Consensus group, which suggests treating the first relapse or infrequent relapse with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum dose of 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    until the proteinuria has resolved for three consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/3\">",
"     3",
"    </a>",
"    ]. At that point, alternate-day prednisone is administered at a dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum dose of 45",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for four weeks. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Children's Nephrotic Syndrome Consensus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Frequent relapsing/steroid dependent NS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in a previously mentioned report from the International Study of Kidney Disease in Children (ISKDC), 30 percent of steroid-responsive patients will develop frequently relapsing NS defined as four or more relapses per year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, there is a group of patients who are steroid dependent (defined as relapsing during taper or within two weeks of discontinuation of steroid therapy).",
"   </p>",
"   <p>",
"    Although children with frequently relapsing or steroid dependent NS are at risk for steroid toxicity,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    remains the preferred therapy in the absence of significant steroid toxicity. Different steroid regimens have been used to treat patients with frequent relapses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are steroid dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ISKDC recommends a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      dose of 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day (maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      be initiated when a patient has relapsed and is continued for three days after the urine has become protein free; thereafter, alternate-day prednisone, 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      is given for four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Children&rsquo;s Nephrotic Syndrome Consensus recommends",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      until the urine protein tests are negative or trace for three consecutive days, followed by alternate-day prednisone of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for four weeks, which is then tapered over two months by 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In our practice, we administer daily",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , 40 to 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      until proteinuria has disappeared for four to five days, followed by alternate-day therapy with tapering by 15 to 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every other day to the patient's steroid threshold (ie, the dose at which the relapse has occurred) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/21\">",
"       21",
"      </a>",
"      ]. This regimen is continued for 12 to 18 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first regimen allows better definition in terms of relapses but is associated with more relapses because of the shorter duration of therapy resulting in larger cumulative steroid dose. The third approach is associated with fewer steroid side effects, as the duration of high-dose therapy is shorter.",
"   </p>",
"   <p>",
"    It is important to appreciate, especially when considering other therapeutic agents that almost all frequent relapsers have a progressive decrease in the number of relapses over time and ultimately go into permanent remission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/22\">",
"     22",
"    </a>",
"    ]. Steroid-sparing agents should be considered in children who have significant steroid toxicity. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Steroid side effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Nonsteroidal therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81224475\">",
"    <span class=\"h4\">",
"     Infections as relapse triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections are a documented trigger for a relapse in children with NS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/23\">",
"     23",
"    </a>",
"    ]. A short-term increase to daily rather than alternate-day maintenance dosing in patients with frequent relapsing SSNS for five to seven days during an episode of intercurrent infections appears to reduce the risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. A randomized controlled trial involving 100 children with frequently relapsing nephritic syndrome found that daily administration of maintenance doses of steroids for seven days during intercurrent infection significantly reduced relapse rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Steroid side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications secondary to prolonged steroid therapy are well known and are seen in children with NS, especially those with frequent relapses or steroid dependency. The side effects associated with steroid use in children with NS are summarized here. Major side effects of steroids are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statural growth impairment can be seen with prolonged daily steroid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/27\">",
"       27",
"      </a>",
"      ]. Low-dose alternate-day therapy can preserve growth [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/28\">",
"       28",
"      </a>",
"      ], and catch-up growth often occurs when steroid therapy is discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/29\">",
"       29",
"      </a>",
"      ]. One small observational study found that growth was not negatively impacted with doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      below 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/30\">",
"       30",
"      </a>",
"      ]. We prefer alternate-day therapy whenever possible to preserve normal growth as much as possible.",
"     </li>",
"     <li>",
"      Cataracts [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excessive weight gain, which can persist into adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although osteoporosis has been reported in adults who had steroid-sensitive NS as children [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/33\">",
"       33",
"      </a>",
"      ], a study that compared adolescents and children with steroid-sensitive NS to control patients by dual energy x-ray absorptiometry (DEXA) found no long-term effects of intermittent high-dose glucocorticoid exposure upon bone mineral content of the spine or body [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suppression of the hypothalamic-pituitary-adrenal axis (HPA). In a case series of patients (mean age of 9.7 years) treated with alternate-day steroids, 20 of 32 patients had evidence of HPA suppression, defined as a peak serum cortisol concentration less than 500",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (18",
"      <span class=\"nowrap\">",
"       &micro;g/dL)",
"      </span>",
"      in response to adrenocorticotrophin stimulation given as a injection of tetracosactide (brand name Synacthen&reg;) (0.5 &micro;g) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/34\">",
"       34",
"      </a>",
"      ]. Although the authors suggest that HPA suppression increased the risk of relapse, the contribution of HPA suppression is uncertain because the patients in this small study were treated with several different regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonsteroidal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with significant side effects of steroid therapy, other steroid-sparing agents (eg, alkylating agents) that prolong remissions and reduce the dose of steroids should be considered. These drugs include alkylating agents, levamisole,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81224860\">",
"    <span class=\"h3\">",
"     Alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkylating agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , can induce longer lasting remissions than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    alone in patients who are frequent relapsers or steroid dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/19,35-37\">",
"     19,35-37",
"    </a>",
"    ]. However, these medications, which result in depletion of immune competent cells, have significant side effects. Based upon the efficacy and safety data discussed in the following sections, if we elect to use an alkylating agent, we will administer a 12-week course of oral cyclophosphamide at a dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (cumulative dose 168 mg). The maximum daily dose should not exceed 2.5",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81225709\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    efficacy of alkylating agents is best illustrated by a meta-analysis that compared alkylating agents with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    alone in maintaining remission in children with SSNS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/19\">",
"     19",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In three trials of 102 patients, oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      reduced the risk of relapse at six to twelve months (RR 0.44; 95% CI 0.26-0.73).",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      given monthly for six months appears to provide a significantly better rate of sustained remission, although the number of children with persistent remission tends to be similar at two years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"       Chlorambucil",
"      </a>",
"      compared with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      reduced the risk for relapse at six months in 41 children (RR 0.19, 95% CI 0.03-1.09) and at 12 months in 32 children (RR 0.13, 95% CI 0.03-0.57).",
"     </li>",
"     <li>",
"      In the one trial of 50 patients that compared",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"       chlorambucil",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , there was no difference in the risk of relapse at 12 and 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supporting observational data demonstrated that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy resulted in sustained remission in frequently relapsing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    steroid dependent patients of 57 to 93 percent at one year, 31 to 66 percent at five years, and approximately 25 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/35-37,39,40\">",
"     35-37,39,40",
"    </a>",
"    ]. However, a more current case series reported lower remission rates of 44, 27, and 13 percent at one, two, and five years after cyclophosphamide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variation in remission rates is likely to be due to differences in the patient population such as the proportion of patients with steroid-dependent NS who appear to have a lower response rate to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study of 50 children, only 30 percent of steroid-dependent patients compared with seventy percent of children with frequent relapses had prolonged remissions after an eight-week oral course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a long-term follow-up report (median time six years) of 93 patients with steroid dependent biopsy-proven minimal change disease, only 35 percent of patients remained in sustained remission after a course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/43\">",
"       43",
"      </a>",
"      ]. Twenty-eight patients (30 percent) had more than five relapses, 19 (20 percent) had five or less relapses, and 13 were lost to follow-up.",
"     </li>",
"     <li>",
"      In another study of 90 patients with steroid dependent NS, a similar sustained remission rate of 31 percent was seen at five year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the degree of steroid dependency may affect remission rates. This was illustrated in a study of 108 patients with steroid-dependent NS treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    who attained overall cumulative sustained remission rates of 25 and 22 percent at 5 and 10 year follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients who relapsed on lower doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (ie, &le;1.4",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    were more likely to have sustained remission at 5 and 10 year follow up compared with those who required higher doses of prednisone (35 and 33 percent versus 13 and 5 percent).",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may also depend upon the duration of treatment, especially in steroid-dependent children. This was demonstrated in a German study in which 18 steroid-dependent children received a 12-week oral course of cyclophosphamide (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients treated for 12 weeks had a higher remission rate at two years compared with historical controls treated for eight weeks (67 versus 30 percent). However, other studies found no difference in length of remission between an 8 and 12 week course of cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/19,46,47\">",
"     19,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, when we elect to use an alkylating agent,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is our drug of choice. We administer a 12-week course of oral cyclophosphamide at a dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (cumulative dose 168 mg). The maximum daily dose of cyclophosphamide should not exceed 2.5",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81224867\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with the use of alkylating agents include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia and infection &ndash; Bone marrow suppression by alkylating agents requires monitoring complete blood cell counts (CBC). If the white cell count falls below",
"      <span class=\"nowrap\">",
"       3000/mm3,",
"      </span>",
"      the drug should be withdrawn until the count rises. Treatment also should be discontinued if infection develops. There are reported cases of significant morbidity and mortality associated with varicella and the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . If varicella infection occurs,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      should be administered immediately and the alkylating agent discontinued. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of idiopathic nephrotic syndrome in children\", section on 'Varicella'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonadal toxicity &ndash; The development of gonadal toxicity resulting in infertility generally requires a total dose greater than 200 to 300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , which exceeds the recommended cumulative dose used to treat children with NS (168",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for cyclophosphamide) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. The gonadal toxicity threshold for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"       chlorambucil",
"      </a>",
"      is 8 to 10",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"     </li>",
"     <li>",
"      Malignancy &ndash; In a 2001 systematic review of the literature that included 1504 patients, 14 cases of malignancies were reported after high doses (greater than the above recommended standard dosing) of either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"       chlorambucil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/49\">",
"       49",
"      </a>",
"      ]. There was also a single reported case of malignancy (acute lymphoblastic leukemia) associated with cyclophosphamide administered in a child with NS using the above recommended regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/52\">",
"       52",
"      </a>",
"      ]. The extensive use of the above standard regimen of cyclophosphamide in children with NS and only a single reported associated case of malignancy suggest that there is",
"      <strong>",
"       not",
"      </strong>",
"      a clinically significant increased risk of malignancy associated with cyclophosphamide at this dosage used to treat childhood NS compared with the general pediatric population.",
"     </li>",
"     <li>",
"      Alopecia and hemorrhagic cystitis rarely occur at the recommended doses used to treat children with NS.",
"     </li>",
"     <li>",
"      Seizures &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"       Chlorambucil",
"      </a>",
"      has been associated with an increased risk of seizures in children with NS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the above data, a 12-week course of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (cumulative dose of 168",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    appears to have minimal long-term complications and is the preferred regimen when an alkylating agent is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Levamisole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levamisole, which stimulates the immune system, has been shown to have a steroid-sparing effect in children with SSNS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/19,54-60\">",
"     19,54-60",
"    </a>",
"    ]. In a meta-analysis that reviewed non-steroid treatment for SSNS, three trials were identified that demonstrated a beneficial effect of levamisole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/19\">",
"     19",
"    </a>",
"    ]. Although there was variation in the duration of treatment, fewer children with SSNS relapsed during levamisole treatment compared with those who received placebo,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , or no treatment (RR 0.5, 95% CI 0.25-0.99). However, most patients relapsed within three months after cessation of treatment.",
"   </p>",
"   <p>",
"    The dose of levamisole is 2 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given on alternate days (maximum dose of 150 mg). Regular monitoring of complete blood count (CBC) should be performed because the most serious adverse effect of levamisole is reversible neutropenia.",
"   </p>",
"   <p>",
"    There is limited availability of levamisole worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/61\">",
"     61",
"    </a>",
"    ], and it is not currently available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitors (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) block T-cell activation and have been used to treat patients with frequently relapsing or steroid-dependent NS. However, long-term therapy is generally required to maintain remission, which increases the risk for drug-induced nephrotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174702127\">",
"    <span class=\"h4\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data demonstrate",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is effective in inducing or maintaining remission in patients with frequently relapsing or steroid-dependent NS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. A review of the literature, which included 129 children, reported cyclosporine either induced remission or maintained remission in 85 percent of patients, thereby allowing withdrawal of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/63\">",
"     63",
"    </a>",
"    ]. However, most patients relapse when the drug is withdrawn, thus necessitating prolonged treatment and increasing the risk of nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/62,68,69\">",
"     62,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the concern for nephrotoxicity, the plasma creatinine concentration should be monitored regularly in patients who are maintained on long-term course of cyclosporin. However, serial renal biopsies demonstrate histologic lesions of nephrotoxicity without clinical evidence of renal function impairment. Thus, we routinely perform a renal biopsy in asymptomatic patients after 18 months of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the previously mentioned meta-analysis that reviewed non-steroidal therapy for SSNS, the effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was initially the same as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"     chlorambucil",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in maintaining remission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/19\">",
"     19",
"    </a>",
"    ]. However, after cyclosporine was discontinued, it was less effective in maintaining remission at 12 months compared with either alkylating agents and at 24 months for chlorambucil.",
"   </p>",
"   <p>",
"    The recommended starting",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    dose is 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day divided into two oral doses. The dose should be adjusted to maintain trough whole blood levels between 100 and 200",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and the level should not exceed 200",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    In order to limit the risk of nephrotoxicity, once remission is achieved, we recommend decreasing the dose to less than 5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    if possible.",
"   </p>",
"   <p>",
"    It has been our experience that patients who relapse on",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or after cyclosporine withdrawal often respond poorly to a second or third course of treatment. Low-dose alternate-day",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    in combination with cyclosporine may be a better approach in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174702253\">",
"    <span class=\"h4\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    offers no advantage over",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    on maintaining remission in children with SSNS, and it has the same risk of nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, one advantage of tacrolimus over cyclosporin is the reduced cosmetic side-effects (hypertrichosis, gum hypertrophy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) inhibits T- and B-cell proliferation. Small studies suggest that mycophenolate mofetil (MMF) is effective in increasing the duration of remission in children with idiopathic NS; however, relapses often occur after the treatment is discontinued in steroid-dependent children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/72-77\">",
"     72-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter, prospective, open-label study, 33 patients with frequently relapsing NS received a six-month course of MMF, while in remission (dose of 600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice a day, maximum dose 1 g) and a tapering dose of alternate-day",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    during the first 16 weeks of the study. One patient relapsed two days into the study. Of the 32 patients who completed the study, 24 remained in remission throughout the six months of MMF therapy. Sixteen patients relapsed when MMF was discontinued and eight remained in remission for 18 to 30 months after discontinuation of MMF.",
"   </p>",
"   <p>",
"    In a small randomized trial comparing MMF (1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), sustained complete remission was achieved in 7 of 12 patients who received MMF and in 11 of 12 patients treated with cyclosporine suggesting that cyclosporine is more effective than MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of MMF include gastrointestinal disturbances (abdominal pain and diarrhea) and hematological abnormalities.",
"   </p>",
"   <p>",
"    Further studies including larger controlled trials are needed to determine whether MMF has a role in the treatment of children with NS. A multicenter trial comparing the effectiveness of MMF to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in steroid-dependent patients is in progress in France.",
"   </p>",
"   <p>",
"    While awaiting further information, MMF appears to be reasonable choice to treat children with SSNS and steroid toxicity because it has similar efficacy to other nonsteroidal agents but with less toxicity than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . In our practice, we prefer to administer MMF as the initial steroid-sparing agent, and prescribe cyclosporin only if the patient fails to respond to MMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports have suggested that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    (RTX), a chimeric anti-CD20 monoclonal antibody that depletes B-cell lymphocytes, may be effective in steroid-dependent or calcineurin inhibitor dependent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. In a case series of 54 children with severe steroid or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -dependent NS, the administration of RTX allowed for discontinuation of one or more immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/82\">",
"     82",
"    </a>",
"    ]. The response to rituximab appears to be better if the patient is in remission at the time of the infusion. Therefore, rituximab should not be administered during a relapse but after remission has been induced by increased doses of steroids. About one-half of patients had mild transient side effects, and no serious adverse events were reported.",
"   </p>",
"   <p>",
"    However, a significant proportion of patients relapse after",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    administration. Most relapses occur simultaneously with the recovery of B-cell lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/83\">",
"     83",
"    </a>",
"    ]. Maintenance therapy with MMF has been shown to be effective in preventing relapse after treatment with rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     Rituximab",
"    </a>",
"    is associated with serious adverse effects including infusion-related reactions (hypotension, fever, and rigors), serious infections, and progressive multifocal leukoencephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/85\">",
"     85",
"    </a>",
"    ]. In addition, there is one published case report of death associated with rituximab therapy in a child with nephrotic syndrome due to lung fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, further studies including controlled trials are needed to determine whether there is a role for RTX in the treatment of children with steroid-dependent or frequently relapsing SSNS as both the efficacy and safety of RTX in this group of patients remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174702557\">",
"    <span class=\"h3\">",
"     Choice of agent: Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with SSNS and evidence of steroid toxicity, the optimal steroid-sparing agent should maintain long-term remission in the majority of patients allowing for a reduction in steroid dosing and toxicity, and have no significant side effects. However, there is no clear evidence that any of the currently used immunosuppressive agents provide long-term efficacy without significant side effects.",
"   </p>",
"   <p>",
"    As noted above, in our practice, we recommend the use of levamisole, if it is available. If this is not the case,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) is our currently preferred drug for patients with significant steroid toxicity. Although data are limited, MMF appears to have similar efficacy to other nonsteroidal immunosuppressive agents but with less toxicity. Other experts in the field have suggested the use of 12-week course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in patients with frequently-relapsing but do not recommend this regimen in those with steroid-dependent NS as the long-term remission rate is much lower and does not warrant the significant potential toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is effective in inducing or maintaining remission in patients with frequently relapsing or steroid-dependent NS, sustained remission requires prolonged treatment and increases the risk of nephrotoxicity. As a result, in our practice, cyclosporine is used in patients that fail to maintain remission after a course of MMF or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    without a significant steroid dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174702759\">",
"    <span class=\"h2\">",
"     Long-term outcome of SSNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on adult long-term outcome of patients who were children with SSNS. At our medical center, 40 percent of the 102 patients born between 1970 and 1975 experienced at least one relapse as an adult [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/33\">",
"     33",
"    </a>",
"    ]. Using multivariate analysis, the number of relapses as a child was the only factor predictive of relapses occurring later in life. Almost half of the adults who relapsed had long-term steroid side effects including osteoporosis and excessive weight gain. One patient developed end-stage renal disease and the remaining patients had normal renal function.",
"   </p>",
"   <p>",
"    A similar adult relapse rate (33 percent) was reported in 42 patients with SSNS treated at another single tertiary center [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/88\">",
"     88",
"    </a>",
"    ]. In this study, multivariate analysis demonstrated that only the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was predictive of relapse in adulthood, suggesting that relapse in adulthood was related to a complicated childhood course of NS. All 42 patients had normal renal function, final adult height, and body mass index.",
"   </p>",
"   <p>",
"    In a small case series of 15 adult patients with frequently relapsing persistent biopsy-proven minimal change disease, all patients had normal GFR, seven were hypertensive, and four of 11 evaluable patients had osteoporosis at median follow-up of 24 years (range 10 to 39 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/15/28922/abstract/89\">",
"     89",
"    </a>",
"    ]. Ophthalmologic examination revealed myopia in 10 patients and cataracts in three. Of the eight male patients who underwent semen examination, six had teratozoospermia, four with reduced sperm motility, and one with oligozoospermia.",
"   </p>",
"   <p>",
"    These results demonstrate that in almost all cases, renal function remains normal in adulthood. Long term sequelae are generally related to side effects of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     STEROID-RESISTANT NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children fail to respond to initial steroid treatment. Evaluation to determine the underlying etiology including a renal biopsy, and screening for genetic disorders should be performed in this setting as therapeutic decisions are based on the underlying cause.",
"   </p>",
"   <p>",
"    The causes and management of steroid-resistant nephrotic syndrome in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=see_link\">",
"     \"Steroid-resistant idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1209920008\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications in children with nephrotic syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection including peritonitis",
"     </li>",
"     <li>",
"      Thromboembolism",
"     </li>",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Anasarca",
"     </li>",
"     <li>",
"      Hypovolemia",
"     </li>",
"     <li>",
"      Impaired growth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications including their management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link\">",
"     \"Complications of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with nephrotic syndrome (NS) who have a high probability of having minimal change disease (MCD) based on clinical and laboratory findings, we recommend empiric therapy with oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , thus avoiding renal biopsy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      We start with oral prednisone at a dose of 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day (maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      When proteinuria disappears, prednisone is continued at the same daily dose for 30 days, followed by alternate-day therapy (at the same daily dose) for two months, after which prednisone is tapered every two weeks by 15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial pharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H20#H20\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Initial therapy versus renal biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most children with idiopathic NS will respond to steroid therapy. After six months of initial steroid therapy, approximately 40 percent of children with steroid-responsive NS will not relapse, 10 to 20 percent will have less than four relapses, and the remaining will have frequent relapses",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      relapse while on steroid therapy (steroid dependent). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Steroid response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 90 percent of responding patients attain complete remission within the first four weeks of steroid therapy, and the remaining 10 percent respond after an additional two to four weeks of steroid therapy. (See",
"      <a class=\"local\" href=\"#H168505\">",
"       'Time to response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with steroid-responsive NS, who are frequent relapsers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      are steroid dependent, often develop evidence of steroid toxicity. In these patients, we recommend treatment with a non-steroidal agent to maintain remission while reducing steroid dosing and toxicity&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Nonsteroidal therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In our practice, our initial steroid-sparing agent of choice is levamisole, if it is available. If this is not the case,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) is our currently preferred drug for patients with significant steroid toxicity. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Levamisole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Mycophenolate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other experts in the field have suggested the use of 12-week course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in patients with frequently-relapsing but do not recommend this regimen in those with steroid-dependent NS as the long-term remission rate is much lower and does not warrant the significant potential toxicity. (See",
"      <a class=\"local\" href=\"#H81224860\">",
"       'Alkylating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      is effective in inducing or maintaining remission in patients with frequently relapsing or steroid-dependent NS, sustained remission requires prolonged treatment and increases the risk of nephrotoxicity. As a result, in our practice, cyclosporine is only used in patients that fail to maintain remission after a course of MMF or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      without a significant steroid dose. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ten percent of children will fail to respond to steroid therapy. These children with steroid-resistant NS are at increased risk for developing end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H174702423\">",
"       'Outcome based upon response'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=see_link\">",
"       \"Steroid-resistant idiopathic nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/1\">",
"      Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/2\">",
"      The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/3\">",
"      Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/4\">",
"      Lombel RM, Gipson DS, Hodson EM. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/5\">",
"      Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/6\">",
"      Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/7\">",
"      Vivarelli M, Moscaritolo E, Tsalkidis A, et al. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr 2010; 156:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/8\">",
"      Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Lancet 1988; 1:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/9\">",
"      Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2005; :CD001533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/10\">",
"      Brodehl J. The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies. Eur J Pediatr 1991; 150:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/11\">",
"      Hiraoka M, Tsukahara H, Matsubara K, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 2003; 41:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/12\">",
"      Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007; :CD001533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/13\">",
"      Leisti S, Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression. J Pediatr 1983; 103:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/14\">",
"      Leonard MB, Feldman HI, Shults J, et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004; 351:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/15\">",
"      Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 2006; 17:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/16\">",
"      MacHardy N, Miles PV, Massengill SF, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 2009; 24:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/17\">",
"      Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/18\">",
"      Murnaghan K, Vasmant D, Bensman A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr Scand 1984; 73:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/19\">",
"      Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 2008; :CD002290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/20\">",
"      Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 1982; 101:514.",
"     </a>",
"    </li>",
"    <li>",
"     Broyer M, Meyrier A, Niaudet P, Habib R. Minimal changes and focal and segmental glomerular sclerosis. In: Oxford Textbook of Clinical Nephrology, Cameron JS, Davison MA, Gr&uuml;nfeld JP, et al (Eds), Oxford Medical Publications, 1992. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/22\">",
"      Welch TR, Gianis J, Sheldon CA. Perforation of the scrotum complicating nephrotic syndrome. J Pediatr 1988; 113:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/23\">",
"      MacDonald NE, Wolfish N, McLaine P, et al. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 1986; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/24\">",
"      Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 2008; 93:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/25\">",
"      Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron 2000; 85:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/26\">",
"      Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/27\">",
"      Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/28\">",
"      Polito C, Oporto MR, Totino SF, et al. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand 1986; 75:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/29\">",
"      FLEISHER DS, McCRORY WW, RAPOPORT M. The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children. J Pediatr 1960; 57:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/30\">",
"      Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child 2010; 95:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/31\">",
"      Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child 1982; 57:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/32\">",
"      Ng JS, Wong W, Law RW, et al. Ocular complications of paediatric patients with nephrotic syndrome. Clin Experiment Ophthalmol 2001; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/33\">",
"      Fakhouri F, Bocquet N, Taupin P, et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 2003; 41:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/34\">",
"      Abeyagunawardena AS, Hindmarsh P, Trompeter RS. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. Arch Dis Child 2007; 92:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/35\">",
"      Cameron JS, Chantler C, Ogg CS, White RH. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. Br Med J 1974; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/36\">",
"      Chiu J, Drummond KN. Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome. J Pediatr 1974; 84:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/37\">",
"      McDonald J, Murphy AV, Arneil GC. Long-term assessment of cyclophosphamide therapy for nephrosis in children. Lancet 1974; 2:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/38\">",
"      Prasad N, Gulati S, Sharma RK, et al. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2004; 19:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/39\">",
"      Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 2003; 18:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/40\">",
"      Azib S, Macher MA, Kwon T, et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/41\">",
"      Cammas B, Harambat J, Bertholet-Thomas A, et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 2011; 26:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/42\">",
"      Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 1982; 306:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/43\">",
"      Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 2007; 49:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/44\">",
"      Zagury A, de Oliveira AL, de Moraes CA, et al. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/45\">",
"      Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Arch Dis Child 1987; 62:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/46\">",
"      Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child 1990; 65:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/47\">",
"      Donia AF, Gazareen SH, Ahmed HA, et al. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant 2003; 18:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/48\">",
"      Trompeter RS. Immunosuppressive therapy in the nephrotic syndrome in children. Pediatr Nephrol 1989; 3:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/49\">",
"      Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/50\">",
"      Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/51\">",
"      Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/52\">",
"      M&uuml;ller W, Brandis M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. A case report and review of the literature. Eur J Pediatr 1981; 136:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/53\">",
"      Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978; 93:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/54\">",
"      Mongeau JG, Robitaille PO, Roy F. Clinical efficacy of levamisole in the treatment of primary nephrosis in children. Pediatr Nephrol 1988; 2:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/55\">",
"      Alsaran K, Grisaru S, Stephens D, Arbus G. Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2001; 56:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/56\">",
"      Barletta GM, Smoyer WE, Bunchman TE, et al. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 2003; 18:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/57\">",
"      Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991; 337:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/58\">",
"      Boyer O, Moulder JK, Grandin L, Somers MJ. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 2008; 23:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/59\">",
"      S&uuml;megi V, Haszon I, Iv&aacute;nyi B, et al. Long-term effects of levamisole treatment in childhood nephrotic syndrome. Pediatr Nephrol 2004; 19:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/60\">",
"      Elmas AT, Tabel Y, Elmas ON. Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome. Int Urol Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/61\">",
"      Davin JC, Merkus MP. Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol 2005; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/62\">",
"      Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994; 5:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/63\">",
"      Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol 1991; 35 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/64\">",
"      Tejani AT, Butt K, Trachtman H, et al. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988; 33:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/65\">",
"      Kano K, Kyo K, Yamada Y, et al. Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome. Clin Nephrol 1999; 52:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/66\">",
"      Mahmoud I, Basuni F, Sabry A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/67\">",
"      Habib R, Niaudet P. Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 1994; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/68\">",
"      Kengne-Wafo S, Massella L, Diomedi-Camassei F, et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 2009; 4:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/69\">",
"      Ishikura K, Yoshikawa N, Nakazato H, et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol 2012; 7:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/70\">",
"      D&ouml;tsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol Dial Transplant 2006; 21:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/71\">",
"      Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/72\">",
"      Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003; 42:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/73\">",
"      Novak I, Frank R, Vento S, et al. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/74\">",
"      Hogg RJ, Fitzgibbons L, Bruick J, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/75\">",
"      Fujinaga S, Ohtomo Y, Umino D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/76\">",
"      Afzal K, Bagga A, Menon S, et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/77\">",
"      Banerjee S, Pahari A, Sengupta J, Patnaik SK. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 2013; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/78\">",
"      Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008; 23:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/79\">",
"      Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/80\">",
"      Fujinaga S, Hirano D, Nishizaki N, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010; 25:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/81\">",
"      Sellier-Leclerc AL, Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/82\">",
"      Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/83\">",
"      Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/84\">",
"      Ito S, Kamei K, Ogura M, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/85\">",
"      Pradhan M, Furth S. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol 2012; 23:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/86\">",
"      Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/87\">",
"      Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/88\">",
"      R&uuml;th EM, Kemper MJ, Leumann EP, et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 2005; 147:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/15/28922/abstract/89\">",
"      Kyrieleis HA, L&ouml;wik MM, Pronk I, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009; 4:1593.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6130 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28922=[""].join("\n");
var outline_f28_15_28922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25158738\">",
"      SOCIETAL GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Children's Nephrotic Syndrome Consensus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25158857\">",
"      KDIGO guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Steroid response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H168505\">",
"      - Time to response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H168465\">",
"      - Length of therapy and risk of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H167764\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174702423\">",
"      Outcome based upon response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STEROID-SENSITIVE NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81224482\">",
"      Steroid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Initial or infrequent relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Frequent relapsing/steroid dependent NS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H81224475\">",
"      Infections as relapse triggers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Steroid side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonsteroidal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81224860\">",
"      - Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H81225709\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H81224867\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Levamisole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H174702127\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H174702253\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174702557\">",
"      - Choice of agent: Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174702759\">",
"      Long-term outcome of SSNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      STEROID-RESISTANT NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1209920008\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6130\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6130|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/47/42751\" title=\"figure 1\">",
"      Response to steroids in MCD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=related_link\">",
"      Evaluation and treatment of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21354?source=related_link\">",
"      Steroid-resistant idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=related_link\">",
"      Symptomatic management of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_15_28923="Eval infants mother with WNV";
var content_f28_15_28923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended clinical evaluation of infants born to mothers infected with West Nile virus (WNV) during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A thorough physical examination of the newborn should",
"be conducted, including careful measurement of the infant's head",
"circumference, length, weight, and assessment of gestational age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The newborn should be evaluated carefully for",
"neurologic abnormalities, dysmorphic features, splenomegaly,",
"hepatomegaly, and rash or other skin lesions. Any rash, skin lesions,",
"or dysmorphic features should be photographed. If an abnormality is",
"noted, consultation with an appropriate specialist is recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant serum should be obtained within 2 days of birth",
"and at about age 8 weeks to test for IgM and IgG antibody to WNV. Free",
"testing of samples by CDC can be arranged by contacting state public",
"health laboratories.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A newborn hearing screen should be completed by evoked",
"otoacoustic emissions testing or auditory brainstem response testing,",
"either before discharge from the hospital or within 1 month after",
"birth. Infants who fail the initial hearing screen should be referred",
"to an audiologist for further evaluation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial examination of the placenta by a pathologist is",
"encouraged. Regardless of whether this is done, the entire placenta, a",
"sample of umbilical cord tissue, and a sample of serum from the",
"umbilical cord should be retained for further evaluation if congenital",
"WNV infection is identified or strongly suspected. A section of the",
"placenta and umbilical cord should be frozen, and the remainder of the",
"placenta should be preserved in formalin; a sample of umbilical cord",
"blood should be centrifuged, and the serum should be refrigerated or",
"frozen.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     www.cdc.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28923=[""].join("\n");
var outline_f28_15_28923=null;
var title_f28_15_28924="Uses of noninvasive ventilation";
var content_f28_15_28924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common uses of noninvasive ventilatory support",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Ventilator",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Typical settings",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Applications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Rate/min",
"      </td>",
"      <td class=\"subtitle2\">",
"       Pressures, cmH2O",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Positive pressure",
"      </td>",
"      <td>",
"       12-22",
"      </td>",
"      <td>",
"       10 to 20 inspiratory 3 to 5 expiratory 12 to 15 mL/kg",
"      </td>",
"      <td>",
"       Mode of first choice. Nasal route preferred, oronasal or mouthpiece if nasal unsuccessful.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Negative pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Iron lung",
"      </td>",
"      <td class=\"sublist1\">",
"       12-14",
"      </td>",
"      <td class=\"sublist1\">",
"       -12 to -25",
"      </td>",
"      <td class=\"sublist1\">",
"       Second line for patients if nasal ventilation fails.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Wrap",
"      </td>",
"      <td class=\"sublist1\">",
"       14-18",
"      </td>",
"      <td class=\"sublist1\">",
"       -20 to -40",
"      </td>",
"      <td class=\"sublist1\">",
"       Sleep apnea should be excluded first.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Shell or cuirass",
"      </td>",
"      <td class=\"sublist1\">",
"       14-18",
"      </td>",
"      <td class=\"sublist1\">",
"       -20 to -40",
"      </td>",
"      <td class=\"sublist1\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Abdominal ventilator",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pneumobelt",
"      </td>",
"      <td class=\"sublist_other\">",
"       16-22",
"      </td>",
"      <td class=\"sublist_other\">",
"       35 to 50",
"      </td>",
"      <td class=\"sublist_other\">",
"       Diaphragm paralysis or weakness; high cord lesion; mainly for daytime use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rocking bed",
"      </td>",
"      <td>",
"       12-16",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Diaphragm paralysis or weakness; mainly for nocturnal use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glossopharyngeal breathing",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Respiratory muscle weakness, but upper airway function intact; post-polio and muscular dystrophy patients.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diaphragm pacing",
"      </td>",
"      <td>",
"       12-14",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Intact phrenic nerve and diaphragm muscle; high cord lesion and central hypoventilation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Expiratory aids",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       To augment peak cough flows in patients with weakened expiratory muscles.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28924=[""].join("\n");
var outline_f28_15_28924=null;
var title_f28_15_28925="HAI correlations";
var content_f28_15_28925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Correlation of HAI with conventional interpretation of liver biopsy specimens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Correlation between the histologic activity index (HAI) and conventional interpretation of liver biopsy specimens from patients with chronic hepatitis. The mean HAI score increased with increasing severity as assessed by conventional qualitative diagnosis.",
"    <div class=\"footnotes\">",
"     CPH: chronic persistent hepatitis; CAH: chronic active hepatitis; and MLH: multilobular necrosis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Knodell RG, Ishak KG, Black WC, et al. Hepatology 1981; 1:431.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28925=[""].join("\n");
var outline_f28_15_28925=null;
var title_f28_15_28926="Classify rhinosinusitis";
var content_f28_15_28926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Classification of rhinosinusitis by duration of disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 221px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28926=[""].join("\n");
var outline_f28_15_28926=null;
var title_f28_15_28927="Course acute dengue infection";
var content_f28_15_28927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Acute dengue virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 384px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypothetical schema of events in acute dengue virus infection. The kinetics and general location of viral replication are diagrammed in relation to the presence of detectable viremia, general symptoms (fever, myalgias, headache, rash), and the period of risk for plasma leakage, shock, severe thrombocytopenia, and bleeding in dengue hemorrhagic fever (DHF). Nonspecific immune responses include the production of interferons (IFN) and natural killer (NK) cell activity. The kinetics of dengue virus-specific T lymphocyte activation and the production of dengue virus-specific antibodies occur later and are of lesser magnitude in primary infections (first exposure to dengue viruses) than in secondary infections (later infection with a second dengue virus serotype).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_15_28927=[""].join("\n");
var outline_f28_15_28927=null;
